Virax Biolabs Corp (VRAX) Price-to-Projected Revenue Ratio

Public company logo of Virax Biolabs Corp (VRAX)

The hiring of virologists and IT specialists to combat infections drove growth, and the projected price-to-sales ratio on GURU.Markets reflects a peak where the metric reached 80.50. Currently, Virax Biolabs Group (VRAX) is implementing ViraxClear systems to expand into the B2B segment, although falling demand for rapid tests and the slow rollout of new products are weighing on capital.

Virax Biolabs Group Limited - VRAX Forward P/S Multiple (period 04/28/2023 - 11/15/2026)

Comprehensive metric breakdowns and analytics for Virax Biolabs Group (VRAX)

- current price and projected stock value:
Summary company analytics:Virax Biolabs Corp VRAX
Manufactured products of Virax Biolabs Corp

Forward P/S relates current market capitalization to projected revenue, determining the premium the market is willing to pay for future income growth. For Virax Biolabs Group (VRAX), this metric reflects expectations for the commercialization of ViraxClear systems, where excessive growth on the forward P/S chart may signal an overvaluation of expansion potential within the B2B diagnostics segment.

Analysis of competing companies

Forward P/S Multiple A (agilent.com)|Quest Corp (DGX) - Market Cap to Future Revenue Ratio|ILMN - Price-to-Projected Revenue Ratio|EXAS - Forward P/S Multiple|RVTY (Revvity) - Forward Price-to-Revenue Multiple|Bio-Rad - Forward Price to Sales|Price-to-Projected Revenue Ratio anbio.com|Forward P/S Multiple Sotera Health Company|Price-to-Projected Revenue Ratio QuidelOrtho (QDEL)|OPK - Market Cap to Future Revenue Ratio|caredx.com - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Maravai LifeSciences Corp (MRVI)|FLGT: Forward Price-to-Revenue Multiple|Forward Price to Sales LAB (Fluidigm)|Cytek Biosciences Inc (CTKB) - Price-to-Projected Revenue Ratio|OSUR: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple XGN|MDXH: Forward Price to Sales|Price-to-Projected Revenue Ratio Lucid Diagnostics Inc. (LUCD)|Price-to-Projected Revenue Ratio PRE (Prenetics Global Limited)|Forward P/S Multiple IMDX (Insight Molecular Diagnostics Inc)|Price to Expected Revenue Ratio TRIB (Trinity Biotech Corp)|PRPH - Price-to-Projected Revenue Ratio|Ainos (AIMD) - Forward Price-to-Revenue Multiple|CoDx (CODX) - Price-to-Projected Revenue Ratio|HSCS (Heart Test Labs) - Price-to-Projected Revenue Ratio|BMRA (Biomerica, Inc.) - Forward P/S Multiple|CDIO (Cardio Diagnostics) - Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Onconetix Corp (ONCO)|Price to Expected Revenue Ratio BJDX|Price-to-Projected Revenue Ratio Vermillion AWH|Accelerate Diagnostics Inc (AXDX) - Market Cap to Future Revenue Ratio|centogene.com - Forward P/S Multiple|ENZ (Enzo Biochem Inc.) - Market Cap to Projected Revenue|Market Cap to Future Revenue Ratio FRES|Market Cap to Future Revenue Ratio GTG Labs (GENE)|ME (23andme.com) - Forward P/S Multiple|Forward P/S Multiple Psychemedics Inc